Scientific article


Published inRevue médicale suisse, vol. 17, no. 723, p. 188-191
Publication date2021

Diabetes is a rapidly evolving discipline, numerous new molecules and recommendations are available. However, these rapid changes are sometimes difficult to follow for general practitioners. Metformin remains the cornerstone of type 2 diabetes treatment after lifestyle modifications, which should always be encouraged before medications. Currently, the best classes to add after metformin seem to be SGLT2 inhibitors and GLP-1 receptor agonists, as these molecules showed some cardiovascular and renal beneficial effects in dedicated studies. Nevertheless, the current pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in trouble finding the right medication. This article will highlight novelties in the field of diabetes during the year 2020.

  • Diabetes Mellitus
  • Type 2/drug therapy/epidemiology
  • General Practitioners
  • Humans
  • Hypoglycemic Agents/therapeutic use
  • Metformin
  • Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
Citation (ISO format)
GARIANI, Karim, JORNAYVAZ, François. Diabétologie. In: Revue médicale suisse, 2021, vol. 17, n° 723, p. 188–191.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation03/24/2021 9:49:00 AM
First validation03/24/2021 9:49:00 AM
Update time03/16/2023 1:21:07 AM
Status update03/16/2023 1:21:07 AM
Last indexation01/17/2024 2:18:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack